دورية أكاديمية
أعرض في EDS

Approach to Lymphoma-Associated Cardiomyopathy.

التفاصيل البيبلوغرافية
العنوان: Approach to Lymphoma-Associated Cardiomyopathy.
المؤلفون: Abouzid MRA; From the Baptist Hospitals of Southeast Texas, Beaumont, TX., Hameed M; College of Medicine, Alfaisal University, Riyadh, Saudi Arabia., Katta MR; Gandhi Medical College, Hyderabad, Telangana, India., Valisekka SS; Sri Venkateshwara Medical College, Tirupati, India.
المصدر: Cardiology in review [Cardiol Rev] 2024 Mar-Apr 01; Vol. 32 (2), pp. 104-109. Date of Electronic Publication: 2022 Sep 21.
نوع المنشور: Review; Journal Article
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 9304686 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-4683 (Electronic) Linking ISSN: 10615377 NLM ISO Abbreviation: Cardiol Rev Subsets: MEDLINE
أسماء مطبوعة: Publication: 1998- : Hagerstown, MD : Lippincott Williams & Wilkins
Original Publication: Baltimore, Md. : Williams & Wilkins, c1993-
مواضيع طبية MeSH: Cardiomyopathies*/chemically induced , Lymphoma*/complications , Lymphoma*/drug therapy , Heart Failure*/drug therapy, Humans ; Animals ; Rats ; Heart ; Antibiotics, Antineoplastic/adverse effects ; Anthracyclines/adverse effects
مستخلص: Cardiomyopathy is a disease of the myocardium that affects the heart structure and function, eventually resulting in heart failure, valvular regurgitation, arrhythmia, or even sudden cardiac death. Occurring following treatment of lymphoma, both Hodgkin's and Non-Hodgkin's, cardiomyopathy is a feared complication in these cancer survivors due to its significant association with morbidity and mortality. A review of the literature was conducted using a combination of keywords including "Cardiomyopathy," "Anthracycline," "Radiation," "Pathogenesis," and "Management." Anthracyclines and radiation are prominent entities explored in the discussion of lymphoma-associated cardiomyopathy, whereby the formation of reactive oxygen species following treatment with both has been seen in the pathogenesis. The current standard of care thus far for anthracycline-induced cardiomyopathy includes heart failure medications such as beta-blockers, angiotensin-converting enzyme inhibitors, aldosterone receptor antagonists, and loop-diuretics. On the other hand, radiation-induced cardiomyopathy management has not been well-established yet in literature, with agents such as antioxidants and anti-inflammatory drugs still being studied in rat models. The treatment approach to cardiotoxicity in a lymphoma patient should consist of a collaboration between the oncologist and cardiologist prior to lymphoma treatment initiation, to stratify the risk of development of cardiomyopathy in the patient, and decide the best chemotherapy or radiotherapy agent, dosing, and surveillance technique.
Competing Interests: Disclosure: The authors have no conflicts of interest to report.
(Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.)
References: Kostakou PM, Kouris NT, Kostopoulos VS, et al. Cardio-oncology: a new and developing sector of research and therapy in the field of cardiology. Heart Fail Rev. 2019;24:91–100.
Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies. Circulation. 1996;93:841–842.
Gandjbakhch E, Redheuil A, Pousset F, et al. Clinical diagnosis, imaging, and genetics of arrhythmogenic right ventricular cardiomyopathy/dysplasia: JACC state-of-the-art review. J Am Coll Cardiol. 2018;72:784–804.
Amin HZ, Amin LZ, Pradipta A. Takotsubo cardiomyopathy: a brief review. J Med Life. 2020;13:3–7.
Towbin JA, Lowe AM, Colan SD, et al. Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA. 2006;296:1867–1876.
Maron BJ, Towbin JA, Thiene G, et al.; American Heart Association; Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; Council on Epidemiology and Prevention. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 2006;113:1807–1816.
Naso P, Falco L, Porcari A, et al. Chapter 2. Epidemiology. In: Sinagra G, Merlo M, Pinamonti B, eds. Dilated Cardiomyopathy: From Genetics to Clinical Management. Springer; 2019:11–16.
Hu L, Luo D, Zhou T, et al. The association between non-Hodgkin lymphoma and organophosphate pesticides exposure: a meta-analysis. Environ Pollut. 2017;231(pt 1):319–328.
Yang L, Dong J, Jiang S, et al. Red and processed meat consumption increases risk for non-hodgkin lymphoma: a PRISMA-compliant meta-analysis of observational studies. Medicine (Baltimore). 2015;94:e1729.
Fallahzadeh H, Cheraghi M, Amoori N, et al. Red meat intake and risk of non-Hodgkin lymphoma: a meta-analysis. Asian Pac J Cancer Prev. 2014;15:10421–10425.
Caini S, Masala G, Gnagnarella P, et al. Food of animal origin and risk of non-Hodgkin lymphoma and multiple myeloma: a review of the literature and meta-analysis. Crit Rev Oncol Hematol. 2016;100:16–24.
Van de Louw A, Lewis AM, Yang Z. Autopsy findings in patients with acute myeloid leukemia and non-Hodgkin lymphoma in the modern era: a focus on lung pathology and acute respiratory failure. Ann Hematol. 2019;98:119–129.
Mutneja R, Shah M, Vyas D, et al. Respiratory failure due to lung involvement with adult T-cell leukemia/lymphoma: case report and review of literature. Conn Med. 2014;78:139–142.
Hikosaka Y, Yano M, Otsuka S, et al. Post-irradiation constrictive pericarditis following thymoma treatment: a report of two cases. Gen Thorac Cardiovasc Surg. 2015;63:413–415.
Abe J, Martin JF, Yeh ET. The future of onco-cardiology: we are not just “Side Effect Hunters.” Circ Res. 2016;119:896–899.
Armstrong GT, Oeffinger KC, Chen Y, et al. Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J Clin Oncol. 2013;31:3673–3680.
Myrehaug S, Pintilie M, Tsang R, et al. Cardiac morbidity following modern treatment for Hodgkin lymphoma: supra-additive cardiotoxicity of doxorubicin and radiation therapy. Leuk Lymphoma. 2008;49:1486–1493.
Ganatra S, Redd R, Hayek SS, et al. Chimeric antigen receptor T-cell therapy-associated cardiomyopathy in patients with refractory or relapsed non-Hodgkin lymphoma. Circulation. 2020;142:1687–1690.
Heidenreich PA, Hancock SL, Vagelos RH, et al. Diastolic dysfunction after mediastinal irradiation. Am Heart J. 2005;150:977–982.
van Nimwegen FA, Ntentas G, Darby SC, et al. Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines. Blood. 2017;129:2257–2265.
Murbraech K, Smeland KB, Holte H, et al. Heart failure and asymptomatic left ventricular systolic dysfunction in lymphoma survivors treated with autologous stem-cell transplantation: a national cross-sectional study. J Clin Oncol. 2015;33:2683–2691.
Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391:1023–1075.
Fermé C, Thomas J, Brice P, et al.; European Organisation for Research and Treatment of Cancer Lymphoma Group, and; Groupe d’Étude des Lymphomes de l’Adulte. ABVD or BEACOPPbaseline along with involved-field radiotherapy in early-stage Hodgkin lymphoma with risk factors: results of the European Organisation for Research and Treatment of Cancer (EORTC)-Groupe d’Étude des Lymphomes de l’Adulte (GELA) H9-U intergroup randomised trial. Eur J Cancer. 2017;81:45–55.
Li X, Liu M, Sun R, et al. Cardiac complications in cancer treatment - a review. Hellenic J Cardiol. 2017;58:190–193.
Tan TC, Neilan TG, Francis S, et al. Anthracycline-induced cardiomyopathy in adults. Compr Physiol. 2015;5:1517–1540.
Shakir DK, Rasul KI. Chemotherapy induced cardiomyopathy: pathogenesis, monitoring and management. J Clin Med Res. 2009;1:8–12.
Menezes KM, Wang H, Hada M, et al. Radiation matters of the heart: a mini review. Front Cardiovasc Med. 2018;5:83.
Stewart FA, Seemann I, Hoving S, et al. Understanding radiation-induced cardiovascular damage and strategies for intervention. Clin Oncol (R Coll Radiol). 2013;25:617–624.
Taylor C, Correa C, Duane FK, et al.; Early Breast Cancer Trialists’ Collaborative Group. Estimating the risks of breast cancer radiotherapy: evidence from modern radiation doses to the lungs and heart and from previous randomized trials. J Clin Oncol. 2017;35:1641–1649.
Tapio S. Pathology and biology of radiation-induced cardiac disease. J Radiat Res. 2016;57:439–448.
Čelutkienė J, Pudil R, López-Fernández T, et al. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). Eur J Heart Fail. 2020;22:1504–1524.
Lewis WD, Lilly S, Jones KL. Lymphoma: diagnosis and treatment. Am Fam Physician. 2020;101:34–41.
Fields PA, Townsend W, Webb A, et al. De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute trial. J Clin Oncol. 2014;32:282–287.
Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al.; ESC Scientific Document Group. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:2768–2801.
Venkatesh P, Kasi A. Anthracyclines. In: StatPearls. StatPearls Publishing; 2022. Available at: https://www.ncbi.nlm.nih.gov/books/NBK538187/ .
Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017;35:893–911.
Cardinale D, Colombo A, Bacchiani G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131:1981–1988.
Odak M, Kayani WT. MUGA scan. In: StatPearls. StatPearls Publishing; 2022. Available at: https://www.ncbi.nlm.nih.gov/books/NBK564365/ .
Manrique CR, Park M, Tiwari N, et al. Diagnostic strategies for early recognition of cancer therapeutics-related cardiac dysfunction. Clin Med Insights Cardiol. 2017;11:1179546817697983.
Shureiqi I, Cantor SB, Lippman SM, et al. Clinical and economic impact of multiple gated acquisition scan monitoring during anthracycline therapy. Br J Cancer. 2002;86:226–232.
Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014;27:911–939.
Cardinale D, Colombo A, Lamantia G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010;55:213–220.
Piper SE, McDonagh TA. Chemotherapy-related cardiomyopathy. Eur Cardiol. 2015;10:19–24.
Teixeira da Silva F, Morais Passos R, Esteves A, et al. Anthracycline cardiotoxicity in a patient with diffuse large B-cell lymphoma: a case report. Cureus. 2020;12:e11038.
Gulati G, Heck SL, Ree AH, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J. 2016;37:1671–1680.
Alexandre J, Cautela J, Ederhy S, et al. Cardiovascular toxicity related to cancer treatment: a pragmatic approach to the American and European Cardio-Oncology Guidelines. J Am Heart Assoc. 2020;9:e018403.
Armenian S, Bhatia S. Predicting and preventing anthracycline-related cardiotoxicity. Am Soc Clin Oncol Educ Book. 2018;38:3–12.
Olivieri J, Perna GP, Bocci C, et al. Modern management of anthracycline-induced cardiotoxicity in lymphoma patients: low occurrence of cardiotoxicity with comprehensive assessment and tailored substitution by nonpegylated liposomal doxorubicin. Oncologist. 2017;22:422–431.
Smith LA, Cornelius VR, Plummer CJ, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer. 2010;10:337.
Gasser CA, Audebrand A, Daglayan A, et al. Prokineticin receptor-1 signaling inhibits dose- and time-dependent anthracycline-induced cardiovascular toxicity via myocardial and vascular protection. J Am Coll Cardiol CardioOnc. 2019;1:84–102.
McGowan JV, Chung R, Maulik A, et al. Anthracycline chemotherapy and cardiotoxicity. Cardiovasc Drugs Ther. 2017;31:63–75.
Chung R, Maulik A, Hamarneh A, et al. Effect of remote ischaemic conditioning in oncology patients undergoing chemotherapy: rationale and design of the ERIC-ONC Study–a single-center, blinded, randomized controlled trial. Clin Cardiol. 2016;39:72–82.
Sárközy M, Varga Z, Gáspár R, et al. Pathomechanisms and therapeutic opportunities in radiation-induced heart disease: from bench to bedside. Clin Res Cardiol. 2021;110:507–531.
Belzile-Dugas E, Eisenberg MJ. Radiation-induced cardiovascular disease: review of an underrecognized pathology. J Am Heart Assoc. 2021;10:e021686.
Bojan A, Torok-Vistai T, Parvu A. Assessment and management of cardiotoxicity in hematologic malignancies. Dis Markers. 2021;2021:6616265.
van Dalen EC, Raphaël MF, Caron HN, et al. Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer. Cochrane Database Syst Rev. 2014;9:CD006647.
López-Fernández T, Martín García A, Santaballa Beltrán A, et al. Cardio-Onco-Hematologia en la practica clinica. Documento de consenso y recomendaciones. Revista Española de Cardiología (English Edition). 2017;70:474–486.
Schamroth Pravda NR, Kornowski R. Unmet needs and therapeutic strategies in cardio-hemato-oncology. Acta Haematol. 2018;140:226–230.
Saleh TA, Al-Rubaye AS, Noori AS, et al. Assessment of anthracycline-induced long-term cardiotoxicity in patients with hematological malignancies. Iraqi J Hematol. 2019;8:63–68.
Conway A, McCarthy AL, Lawrence P, et al. The prevention, detection and management of cancer treatment-induced cardiotoxicity: a meta-review. BMC Cancer. 2015;15:366.
المشرفين على المادة: 0 (Antibiotics, Antineoplastic)
0 (Anthracyclines)
تواريخ الأحداث: Date Created: 20220921 Date Completed: 20240202 Latest Revision: 20240202
رمز التحديث: 20240202
DOI: 10.1097/CRD.0000000000000471
PMID: 36129332
قاعدة البيانات: MEDLINE
الوصف
تدمد:1538-4683
DOI:10.1097/CRD.0000000000000471